American Journal of Kidney Diseases
Volume 51, Issue 6 , Pages 952-965 , June 2008

A 1-Year Randomized Trial of Calcium Acetate Versus Sevelamer on Progression of Coronary Artery Calcification in Hemodialysis Patients With Comparable Lipid Control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) Study

  • Wajeh Qunibi, MD

      Affiliations

    • Department of Medicine, Division of Nephrology, University of Texas Health Sciences Center, San Antonio, TX
    • Corresponding Author InformationAddress correspondence to Wajeh Y. Qunibi, MD, Professor of Medicine, Medical Director of Dialysis Services, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229-3900.
    • ,
  • Moustafa Moustafa, MD

      Affiliations

    • South Carolina Nephrology and Hypertension, Orangeburg, SC
    • ,
  • Larry R. Muenz, PhD

      Affiliations

    • Larry R. Muenz & Associates, Gaithersburg, MD
    • ,
  • David Y. He, MS

      Affiliations

    • Larry R. Muenz & Associates, Gaithersburg, MD
    • ,
  • Paul D. Kessler, MD

      Affiliations

    • Nabi Biopharmaceuticals, Rockville, MD
    • ,
  • Jose A. Diaz-Buxo, MD

      Affiliations

    • Fresenius Medical Care, Waltham, MA
    • ,
  • Mathew Budoff, MD

      Affiliations

    • Los Angeles Biomedical Research Institute at Harbor UCLA, Torrance, CA.
    • ,
  • CARE-2 Investigators

Received 30 October 2007 ,Accepted 26 February 2008.

References 

  1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(suppl 3):S112–S119
  2. Lindner A, Charra B, Sherrard D, Scribner B. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697–702
  3. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for the development of cardiovascular disease (A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention). Hypertension. 2005;42:1050–1065
  4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218
  5. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131–2138
  6. Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000;15:218–223
  7. Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed tomographic coronary calcium scanning: A review and guidelines for use in asymptomatic persons. Mayo Clin Proc. 1999;74:243–252
  8. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron beam computed tomography and coronary atherosclerotic plaque area: A histopathological correlative study. Circulation. 1995;92:2157–2162
  9. Achenbach S, Moshage W, Ropers D, Nossen J, Daniel WG. Value of electron-beam computed tomography for the noninvasive detection of high-grade coronary-artery stenoses and occlusions. N Engl J Med. 1998;339:1964–1971
  10. Arad Y, Roth M, Newstein D, et al. Coronary calcification, coronary risk factors, and atherosclerotic cardiovascular disease events (The St. Francis Heart Study). J Am Coll Cardiol. 2005;46:158–165
  11. Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of coronary artery disease by cardiac computed tomography: A Scientific Statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation. 2006;114:1761–1791
  12. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft F. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996;27:394–401
  13. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483
  14. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients (A link between end-stage renal disease and cardiovascular disease?). J Am Coll Cardiol. 2002;39:695–701
  15. London GM, Guerin AP, Marchais SJ, Métivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18:1731–1740
  16. Qunibi W. Reducing the burden of cardiovascular calcification in patients with chronic kidney disease. J Am Soc Nephrology. 2005;16(suppl 2):S95–S102
  17. Chertow GM, Burke SK, Raggi P Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–252
  18. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815–1824
  19. Chertow GM, Burke SK, Dillon MA, et al. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant. 1999;14:2907–2914
  20. Ferramosca E, Burke S, Chasan-Taber S, et al. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J. 2005;149:820–825
  21. Phan O, Ivanovski O, Nguyen-Khoa T, et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E–deficient mice. Circulation. 2005;112:2875–2882
  22. Ansari A, Kaupke CJ, Vaziri ND, et al. Cardiac pathology in patients with end-stage renal disease maintained on hemodialysis. Int J Artif Organs. 1993;16:31–36
  23. Rostand SG, Kirk KA, Rutsky EA. The epidemiology of coronary artery disease in patients on maintenance hemodialysis: Implications for management. Contrib Nephrol. 1986;52:34–41
  24. Haydar AA, Hujairi NM, Covic A, et al. Coronary artery calcification is related to coronary atherosclerosis in chronic kidney disease patients: A study comparing EBCT-generated coronary artery calcium scores and coronary angiography. Nephrol Dial Transplant. 2004;19:2307–2312
  25. Qunibi WY. Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). Kidney Int Suppl. 2005;95:S43–S50
  26. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med. 1998;339:1972–1978
  27. Achenbach S, Ropers D, Pohle K, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: A prospective evaluation. Circulation. 2002;106:1077–1082
  28. Budoff MJ, Lane KL, Bakhsheshi H, et al. Rates of progression of coronary calcium by electron beam tomography. Am J Cardiol. 2000;86:8–11
  29. Raggi P, Davidson M, Callister TQ, et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering With EBT Scanning (BELLES). Circulation. 2005;112:563–571
  30. Houslay ES, Cowell SJ, Prescott RJ, et al. Scottish Aortic Stenosis and Lipid Lowering Therapy, Impact on Regression (SALTIRE) Trial Investigators Progressive coronary calcification despite intensive lipid-lowering treatment: A randomised controlled trial. Heart. 2006;92:1207–1212
  31. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389–2397
  32. Wanner C, Krane V, Marz W, et al. German Diabetes and Dialysis Study Investigators Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. [published erratum in N Engl J Med 353:1640, 2005] N Engl J Med. 2005;353:238–248
  33. Budoff MJ, Georgiou D, Brody AS, et al. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: A multicenter study. Circulation. 1996;93:898–904
  34. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827–832
  35. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: Wiley; 1987;
  36. Qunibi WY, Nolan CR, Ayus JC. Cardiovascular calcification in patients with end-stage renal disease: A century-old phenomenon. Kidney Int Suppl. 2002;82:73–80
  37. McCullough PA, Sandberg KR, Dumler F, Yanez JE. Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: A systematic review. J Nephrol. 2004;17:205–215
  38. Hoeg JM, Feuerstein IM, Tucker EE. Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb. 1994;14:1066–1074
  39. Son B-K, Kozaki K, Iijima K, et al. Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring gas6-axl survival pathway. Circ Res. 2006;98:1024–1031
  40. Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation: A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol. 1997;17:680–687
  41. Proudfoot D, Davis JD, Skepper JN, et al. Acetylated low-density lipoprotein stimulates human vascular smooth muscle cell calcification by promoting osteoblastic differentiation and inhibiting phagocytosis. Circulation. 2002;106:3044–3050
  42. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol. 2005;96(suppl 1):24F–33F
  43. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72:1130–1137
  44. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71:438–441
  45. McFarlane PA. Sevelamer and extension studies. Kidney Int. 2007;72:225–226

 A list of the CARE-2 Investigators appears at the end of this article.

 Trial registration: www.clinicaltrials.gov; study number: NCT00211939.

 Originally published online as doi:10.1053/j.ajkd.2008.02.298 on April 17, 2008.

PII: S0272-6386(08)00526-X

doi: 10.1053/j.ajkd.2008.02.298

American Journal of Kidney Diseases
Volume 51, Issue 6 , Pages 952-965 , June 2008

Article Tools

* Image Usage & Resolution